The stock of Cempra Inc (NASDAQ:CEMP) is a huge mover today! The stock decreased 4.50% or $1.09 during the last trading session, hitting $23.11. About 1.84 million shares traded hands or 109.87% up from the average. Cempra Inc (NASDAQ:CEMP) has risen 37.15% since March 1, 2016 and is uptrending. It has outperformed by 24.94% the S&P500.
The move comes after 8 months negative chart setup for the $1.22B company. It was reported on Oct, 4 by Barchart.com. We have $21.49 PT which if reached, will make NASDAQ:CEMP worth $85.40 million less.
Analysts await Cempra Inc (NASDAQ:CEMP) to report earnings on October, 27. They expect $-0.64 earnings per share, down 1.59% or $0.01 from last year’s $-0.63 per share. After $-0.51 actual earnings per share reported by Cempra Inc for the previous quarter, Wall Street now forecasts 25.49% negative EPS growth.
Cempra Inc (NASDAQ:CEMP) Ratings Coverage
Out of 9 analysts covering Cempra (NASDAQ:CEMP), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. Cempra has been the topic of 13 analyst reports since July 30, 2015 according to StockzIntelligence Inc. Stifel Nicolaus maintained the stock with “Buy” rating in Friday, June 24 report. The stock has “Mkt Perform” rating given by Leerink Swann on Tuesday, October 13. The firm has “Outperform” rating given on Tuesday, September 13 by Raymond James. The firm earned “Buy” rating on Tuesday, June 7 by Roth Capital. The rating was initiated by Janney Capital on Friday, December 11 with “Buy”. The company was initiated on Thursday, August 13 by Morgan Stanley. The firm earned “Buy” rating on Tuesday, August 2 by Jefferies. Needham maintained Cempra Inc (NASDAQ:CEMP) on Thursday, July 30 with “Buy” rating. The firm has “Buy” rating by TH Capital given on Monday, October 19. As per Monday, November 16, the company rating was upgraded by Morgan Stanley.
According to Zacks Investment Research, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina.”
Insitutional Activity: The institutional sentiment increased to 2.27 in Q2 2016. Its up 0.72, from 1.55 in 2016Q1. The ratio increased, as 10 funds sold all Cempra Inc shares owned while 23 reduced positions. 14 funds bought stakes while 61 increased positions. They now own 39.80 million shares or 3.16% more from 38.58 million shares in 2016Q1.
Invesco Limited accumulated 0% or 422,216 shares. Proshare Ltd Liability Corp has 0.01% invested in the company for 40,947 shares. Moreover, Credit Suisse Ag has 0% invested in Cempra Inc (NASDAQ:CEMP) for 52,074 shares. Fred Alger holds 41,150 shares or 0% of its portfolio. Columbia Prns L L C Invest Mngmt holds 0.31% or 252,998 shares in its portfolio. Alliancebernstein L P holds 0% of its portfolio in Cempra Inc (NASDAQ:CEMP) for 67,200 shares. Jpmorgan Chase holds 277,875 shares or 0% of its portfolio. Blackrock Limited Liability Corp accumulated 20,238 shares or 0% of the stock. The California-based Acuta Capital Prns Limited Liability Company has invested 1.66% in Cempra Inc (NASDAQ:CEMP). Morgan Stanley accumulated 38,728 shares or 0% of the stock. Teachers Advisors has 0% invested in the company for 88,849 shares. Kcg Holdg Inc accumulated 0.01% or 27,553 shares. Rice Hall James & Assoc Lc holds 0.14% of its portfolio in Cempra Inc (NASDAQ:CEMP) for 145,519 shares. Loring Wolcott & Coolidge Fiduciary Advsrs Llp Ma, a Massachusetts-based fund reported 460 shares. Pnc Svcs Group accumulated 148 shares or 0% of the stock.
Another recent and important Cempra Inc (NASDAQ:CEMP) news was published by Fool.com which published an article titled: “3 Reasons Why Cempra, Inc. Rallied 10.99% in May” on June 09, 2016.
CEMP Company Profile
Cempra, Inc., incorporated on May 16, 2008, is a clinical-stage pharmaceutical company. The Firm is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. The Firm also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.